Drug Profile
ISIS 325568
Latest Information Update: 30 Jun 2010
Price :
$50
*
At a glance
- Originator Isis Pharmaceuticals
- Class Antihyperglycaemics; Antisense oligonucleotides
- Mechanism of Action Glucagon receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Type 2 diabetes mellitus
Most Recent Events
- 29 Jun 2010 Efficacy and adverse events data from a phase I trial in Type-2 diabetes mellitus presented presented at the 70th Annual Scientific Sessions of the American Diabetes Association (ADA-2010)
- 02 Oct 2007 The agreement between Isis and Ortho-McNeil receives clearance under the Hart-Scott-Rodino Antitrust Improvements Act
- 17 Sep 2007 Isis and Ortho-McNeil, a Johnson & Johnson company, enter into a worldwide collaboration agreement for antisense drugs for metabolic diseases, including ISIS 325568